Organon & Co. (NYSE:OGN) Upgraded to “Hold” at TD Cowen

TD Cowen upgraded shares of Organon & Co. (NYSE:OGN) to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.

Separately, Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $21.33.

Organon & Co. Trading Down 2.6 %

Shares of NYSE OGN opened at $15.77 on Wednesday. The business has a 50 day simple moving average of $15.32 and a 200 day simple moving average of $18.24. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The stock has a market cap of $4.06 billion, a price-to-earnings ratio of 3.13, a PEG ratio of 0.86 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 earnings per share. On average, research analysts predict that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.10%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s dividend payout ratio is currently 22.22%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Organon & Co. by 2.0% in the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock valued at $81,288,000 after purchasing an additional 82,220 shares during the last quarter. AQR Capital Management LLC boosted its stake in Organon & Co. by 39.8% during the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock valued at $71,905,000 after purchasing an additional 988,336 shares during the period. Deprince Race & Zollo Inc. grew its holdings in Organon & Co. by 6.8% in the 2nd quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company’s stock valued at $70,829,000 after buying an additional 216,907 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Organon & Co. by 35.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after buying an additional 875,128 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Organon & Co. by 23.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock worth $49,843,000 after buying an additional 463,216 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.